Skip to main content
. Author manuscript; available in PMC: 2010 Jul 1.
Published in final edited form as: Ann Neurol. 2009 Jul;66(1):48–54. doi: 10.1002/ana.21623

Figure 2. Concentration of LY450139 in cerebral-spinal fluid during production and clearance of Aβ during and after labeling.

Figure 2

A) There are dose-dependent increases in the concentration of LY450139 in cerebral-spinal fluid with the majority of drug present in the central nervous system during the first twelve hours. B) The absolute amount of newly generated Aβ (labeled) was measured during exposure to placebo or the γ-secretase inhibitor LY450139. The production phase (hours 1–12) and clearance phase (hours 24–36) indicate the time period of analysis for production and clearance of labeled Aβ.